Literature DB >> 2458920

Small finger protein of avian and murine retroviruses has nucleic acid annealing activity and positions the replication primer tRNA onto genomic RNA.

A C Prats1, L Sarih, C Gabus, S Litvak, G Keith, J L Darlix.   

Abstract

Retrovirus virions carry a diploid genome associated with a large number of small viral finger protein molecules which are required for encapsidation. Our present results show that finger protein p12 of Rous sarcoma virus (RSV) and p10 of murine leukaemia virus (MuLV) positions replication primer tRNA on the replication initiation site (PBS) at the 5' end of the RNA genome. An RSV mutant with a Val-Pro insertion in the finger motif of p12 is able to partially encapsidate genomic RNA but is not infectious because mutated p12 is incapable of positioning the replication primer, tRNATrp. Since all known replication competent retroviruses, and the plant virus CaMV, code for finger proteins analogous to RSV p12 or MuLV p10, the initial stage of reverse transcription in avian, mammalian and human retroviruses and in CaMV is probably controlled in an analogous way.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458920      PMCID: PMC457168          DOI: 10.1002/j.1460-2075.1988.tb03008.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  45 in total

1.  Reverse transcriptase mediated binding of primer tRNA to the viral genome.

Authors:  A Araya; L Sarih; S Litvak
Journal:  Nucleic Acids Res       Date:  1979-08-24       Impact factor: 16.971

2.  Cloning and nucleotide sequences of cDNAs spanning the splice junctions of Rous sarcoma virus mRNAs.

Authors:  L J Chang; C M Stoltzfus
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

3.  Correct integration of retroviral DNA in vitro.

Authors:  P O Brown; B Bowerman; H E Varmus; J M Bishop
Journal:  Cell       Date:  1987-05-08       Impact factor: 41.582

4.  A conserved cis-acting sequence in the 5' leader of avian sarcoma virus RNA is required for packaging.

Authors:  R A Katz; R W Terry; A M Skalka
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

5.  Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol.

Authors:  R Moore; M Dixon; R Smith; G Peters; C Dickson
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

6.  Identification of a sequence likely to be required for avian retroviral packaging.

Authors:  T Pugatsch; D W Stacey
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

7.  Synthesis of murine leukemia virus proteins associated with virions assembled in actinomycin D-treated cells: evidence for persistence of viral messenger RNA.

Authors:  J G Levin; M J Rosenak
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

8.  Stoichiometry and specificity of binding of Rauscher oncovirus 10,000-dalton (p10) structural protein to nucleic acids.

Authors:  M Schulein; W N Burnette; J T August
Journal:  J Virol       Date:  1978-04       Impact factor: 5.103

9.  The Drosophila developmental gene snail encodes a protein with nucleic acid binding fingers.

Authors:  J L Boulay; C Dennefeld; A Alberga
Journal:  Nature       Date:  1987 Nov 26-Dec 2       Impact factor: 49.962

10.  Recombination in a plant virus: template-switching in cauliflower mosaic virus.

Authors:  N Grimsley; T Hohn; B Hohn
Journal:  EMBO J       Date:  1986-04       Impact factor: 11.598

View more
  127 in total

1.  In vitro evidence for the interaction of tRNA(3)(Lys) with U3 during the first strand transfer of HIV-1 reverse transcription.

Authors:  F Brulé; G Bec; G Keith; S F Le Grice; B P Roques; B Ehresmann; C Ehresmann; R Marquet
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

2.  The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure.

Authors:  B Berkhout; J L van Wamel
Journal:  RNA       Date:  2000-02       Impact factor: 4.942

3.  Identification of residues of the Moloney murine leukemia virus nucleocapsid critical for viral DNA synthesis in vivo.

Authors:  J Gonsky; E Bacharach; S P Goff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  The human immunodeficiency virus type 1 Gag polyprotein has nucleic acid chaperone activity: possible role in dimerization of genomic RNA and placement of tRNA on the primer binding site.

Authors:  Y X Feng; S Campbell; D Harvin; B Ehresmann; C Ehresmann; A Rein
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.

Authors:  X Li; C Liang; Y Quan; R Chandok; M Laughrea; M A Parniak; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Interaction between retroviral U5 RNA and the T psi C loop of the tRNA(Trp) primer is required for efficient initiation of reverse transcription.

Authors:  A Aiyar; D Cobrinik; Z Ge; H J Kung; J Leis
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  An analytical study of the dimerization of in vitro generated RNA of Moloney murine leukemia virus MoMuLV.

Authors:  C Roy; N Tounekti; M Mougel; J L Darlix; C Paoletti; C Ehresmann; B Ehresmann; J Paoletti
Journal:  Nucleic Acids Res       Date:  1990-12-25       Impact factor: 16.971

Review 8.  Nucleic acid chaperone activity of retroviral Gag proteins.

Authors:  Alan Rein
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

Review 9.  Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function.

Authors:  Gilles Mirambeau; Sébastien Lyonnais; Robert J Gorelick
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

10.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.